SCHEMBL4130668

SCHEMBL4130668

CC1CCCN1C1CCc2cc(-c3cccc(C(F)(F)F)c3)ccc2C1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ASIC3 Q9UHC3 1/20 0.46
MCHR1 Q99705 3/20 0.40
KCNH2 Q12809 1/20 0.40
HRH3 Q9Y5N1 1/20 0.39
HTR1A P08908 1/20 0.39
HTR7 P34969 1/20 0.39
PARP10 Q53GL7 1/20 0.38
PARP11 Q9NR21 1/20 0.38
CTSD P07339 1/20 0.38
CYP11B1 P15538 1/20 0.38
CYP11B2 P19099 1/20 0.38
SPHK2 Q9NRA0 1/20 0.37
SPHK1 Q9NYA1 1/20 0.37
KDM2B Q8NHM5 1/20 0.37
KDM1A O60341 2/20 0.37
MAOA P21397 1/20 0.36
MAOB P27338 1/20 0.36
HTR2A P28223 1/20 0.36
HTR2C P28335 1/20 0.36
HTR2B P41595 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4140086 0.91 KCNH2 (0.37) ASIC3MCHR1KCNH2HRH3HTR1A
SCHEMBL4139561 0.90 MCHR1 (0.40) ASIC3MCHR1KCNH2HRH3CTSD
SCHEMBL4132406 0.85 MCHR1 (0.37) ASIC3MCHR1KCNH2HRH3HTR1A
SCHEMBL4129121 0.85 HRH3 (0.39) ASIC3KCNH2HRH3CTSDCYP11B1
SCHEMBL4142343 0.85 HRH3 (0.40) ASIC3KCNH2HRH3CTSDCYP11B1
SCHEMBL4139527 0.84 HTR2A (0.36) ASIC3MCHR1KCNH2CTSDCYP11B1
SCHEMBL4140975 0.84 USP30 (0.45) MCHR1HRH3CYP11B1CYP11B2
SCHEMBL4141100 0.84 HRH3 (0.38) ASIC3KCNH2HRH3PARP10PARP11
SCHEMBL4135773 0.83 CYP11B1 (0.37) ASIC3KCNH2HRH3CYP11B1CYP11B2
SCHEMBL4136956 0.82 HRH3 (0.38) ASIC3MCHR1KCNH2HRH3CYP11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090163482-A1 TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR MCHARDY STANTON FURST 2009-06-25 US claimed
EP-2007749-A2 TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR Pfizer Products Inc. (US) 2008-12-31 EP claimed
WO-2007105053-A2 TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR PFIZER PRODUCTS INC. (US) 2007-09-20 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090163482-A1 TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR HRH3, HRH4, HRH1 ASIC3 388/4885MCHR1 287/4885KCNH2 657/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.